This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat
by Aparajita Dutta
Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential.
Healthcare ETFs to Buy as UnitedHealth Beats on Q3 Earnings
by Aparajita Dutta
UnitedHealth's Q3 earnings beat estimates, lifting shares 6.3%. Explore three healthcare ETFs offering UNH exposure while diversifying Medicaid risks.
Bet on These Healthcare ETFs to Benefit From the Aging US Population
by Aparajita Dutta
With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.
Consumer Sentiment Drops in September: ETFs to Consider
by Yashwardhan Jain
Consumer sentiment falls to a four-month low amid persistent inflation and uncertainty. Here are some ETFs that investors may consider.
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch
by Aparajita Dutta
UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.
ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook
by Aparajita Dutta
Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.
Are the Odds of a Wider Middle East Conflict Rising? ETFs to Consider
by Yashwardhan Jain
Nine consecutive days of U.S. airstrikes and ongoing retaliatory attacks have heightened fears of a broader Middle East conflict. Here are some ETFs that could benefit.
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
by Aparajita Dutta
JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.